drugset / Trial / NCT03362294
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase IIa study with GA Depot in subjects with Primary Progressive MS. GA Depot will be administered intramuscularly (IM), once every four weeks for 148 weeks. The purpose of this study is to assess the safety and efficacy of GA Depot to slow the accumulation of disability progression in subjects with Primary Progressive MS.
Timeline
- Start
- 2017-12-11
- Primary completion
- 2025-06-20
- Completion
- 2025-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glatiramer Acetate | Small molecule | 25 mg | Intramuscular |
| Subject | Glatiramer Acetate | Small molecule | 40 mg | Intramuscular |